About Glympse Bio
Glympse Bio is a company based in Cambridge (United States) founded in 2015 was acquired by Sunbird Bio in August 2023. Glympse Bio has raised $79.39 million across 6 funding rounds from investors including Gilead, New Leaf Venture Partners and Sunbird Bio. The company has 21 employees as of December 31, 2022. Glympse Bio operates in a competitive market with competitors including Alamar Biosciences, Harmonic Discovery, Seahorse Bioscience, Luceome Biotechnologies and BiOD, among others.
- Headquarter Cambridge, United States
- Employees 21 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$79.39 M (USD)
in 6 rounds
-
Latest Funding Round
$46.7 M (USD), Series B
May 29, 2020
-
Investors
Gilead
& 18 more
-
Employee Count
21
as on Dec 31, 2022
-
Acquired by
Sunbird Bio
(Aug 09, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Glympse Bio
Unlock access to complete
Unlock access to complete
Funding Insights of Glympse Bio
Glympse Bio has successfully raised a total of $79.39M across 6 strategic funding rounds. The most recent funding activity was a Series B round of $46.7 million completed in May 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Glympse Bio
Glympse Bio has secured backing from 19 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Gilead, New Leaf Venture Partners and Sunbird Bio.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are made in innovative technology startups.
|
Locked | Locked | Locked | |
|
An investment platform is provided for diverse sectors and geographies.
|
Locked | Locked | Locked | |
|
US private equity investments are managed by DNS Capital.
|
Locked | Locked | Locked |
Investor details for Glympse Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Glympse Bio
Investment portfolio details for Glympse Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Glympse Bio
Detailed financials for Glympse Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Glympse Bio Comparisons
Peer comparison for Glympse Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Glympse Bio
Glympse Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alamar Biosciences, Harmonic Discovery, Seahorse Bioscience, Luceome Biotechnologies and BiOD, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Ultra-high sensitivity protein analysis solutions are provided across multiplex levels.
|
|
| Locked | Locked | Locked |
Developer of kinase inhibitor drugs for oncology
|
|
| Locked | Locked | Locked |
Cellular metabolic status is measured via the Seahorse XFp Analyzer.
|
|
| Locked | Locked | Locked |
Assay technology is developed for identifying drugs against kinases.
|
|
| Locked | Locked | Locked |
Develops innovative in-vitro diagnostic platforms using optical interrogation of biochip-kits.
|
Detailed competitors of Glympse Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Glympse Bio
Complete news archive for Glympse Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Glympse Bio
Glympse Bio was founded in 2015.
Glympse Bio is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Glympse Bio is a funded company, having raised a total of $79.39M across 6 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Glympse Bio is 21.
Glympse Bio was founded in 2015 in Cambridge, United States, within the biotechnology sector focused on diagnostics. Noninvasive and predictive monitoring of various human diseases is facilitated by engineered diagnostic sensors that detect disease states in the body. Urine samples are analyzed using customized delivery routes and multiplexed analytical platforms. Operations emphasize urine-based interrogation for early disease identification across multiple conditions.
Glympse Bio's top competitors include Alamar Biosciences, Harmonic Discovery and Seahorse Bioscience.
Glympse Bio has 19 investors. Key investors include Gilead, New Leaf Venture Partners, Sunbird Bio, HHS, and Temasek.